SOUTH SAN FRANCISCO, Calif., April 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 13th International Myeloma Workshop (IMW), May 3-6, 2011, in Paris, France.

"The data we are accumulating for carfilzomib continues to support its potential as an important new treatment option for patients with multiple myeloma.  Data from several studies will be presented at the upcoming IMW meeting, including interim data in newly diagnosed patients from a Multiple Myeloma Research Consortium study being led by Dr. Andrzej Jakubowiak at the University of Michigan Comprehensive Cancer Center that is evaluating carfilzomib in combination with a standard therapy," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals. "Onyx is committed to bringing this promising therapy to patients as quickly as possible and remains on track for filing a new drug application with the U.S. Food and Drug Administration as early as mid-year under the accelerated approval process.  We are also actively enrolling patients in the Phase 3 FOCUS trial for the treatment of patients with relapsed and refractory myeloma to support a filing with the European Medicines Agency, as well as, in the Phase 3 ASPIRE trial in relapsed multiple myeloma."

Carfilzomib data highlights include:

Carfilzomib and other new proteasome inhibitors: Clinical data

  • Andrzej Jakubowiak, M.D., Ph.D., University of Michigan Comprehensive Cancer Center, USA
  • Thursday, May 5, 2011, 14:19 – 14:31
  • Oral Session Name: Plenary Session I: New Drugs and Therapeutic Approaches

Results of PX-171